Teprotumumab
Teprotumumab may reduce need for orbital decompression in thyroid eye disease
A decrease in the number of orbital decompression surgeries in patients with thyroid eye disease may be attributed to the introduction of teprotumumab treatment, according to a study published in Canadian Journal of Ophthalmology.
Teprotumumab does not raise rates of hearing-related adverse events in thyroid eye disease
Adults receiving teprotumumab for the treatment of thyroid eye disease experience a similar number of hearing-related adverse events as those not treated with teprotumumab, according to new data.
Hearing loss with teprotumumab more likely for adults with baseline hearing dysfunction
Hearing loss occurred more frequently among adults who received teprotumumab for the treatment of thyroid eye disease if they had impaired hearing at the start of therapy, according to a research letter published in Thyroid.
Will teprotumumab supplant traditional options in the treatment of thyroid eye disease?
Teprotumumab has marked the dawn of a new era in the treatment of thyroid eye disease.
Treatment for thyroid eye disease enters new era, shows potential for brighter future
Until recently, patients with active thyroid eye disease had limited options for treatment of their condition besides observation.
Teprotumumab reduces proptosis in long-standing, stable thyroid eye disease
Adults with long-standing thyroid eye disease and low clinical activity scores had greater reductions in proptosis with teprotumumab compared with placebo, according to data published in The Journal of Clinical Endocrinology & Metabolism.
Amgen clear to acquire Horizon after agreement with Federal Trade Commission
Amgen has reached a deal with the Federal Trade Commission that will enable the pharmaceutical company to complete its $28 billion acquisition of Horizon, according to statements from both parties.
Teprotumumab, tocilizumab improve thyroid eye disease symptoms within 24 weeks
Both teprotumumab and tocilizumab reduce inflammation and thyroid eye disease severity, including among adults who were nonresponders to steroid treatment, according to findings published in Thyroid.
Teprotumumab has been game changer in management of thyroid eye disease
Thyroid eye disease is a debilitating, inflammatory autoimmune condition associated with Graves’ disease that is hard for patients, both physically and psychologically.
Federal Trade Commission sues to block Amgen’s acquisition of Horizon
The Federal Trade Commission has sued to stop Amgen from acquiring Horizon Therapeutics, a potential blockbuster deal that could restrict marketplace competition, according to an FTC press release.